Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    1,608 result(s) found. Displaying page 28 of 81.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next» Last»»
    EudraCT Number: 2014-003647-34 Sponsor Protocol Number: AMLSG23-14/Palbo-AL-1 Start Date*: 2015-05-19
    Sponsor Name:University Hospital Ulm
    Full Title: Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias
    Medical condition: Acute myeloid leukemia Acute lymphoblastic leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004003-23 Sponsor Protocol Number: ISIS703802 Start Date*: 2016-09-28
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S...
    Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10054380 Familial hypercholesterolemia LLT
    19.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    19.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004860-39 Sponsor Protocol Number: TIGET-BTHAL Start Date*: 2015-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment ...
    Medical condition: Beta talassemia trasfusione dipendente
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002135-34 Sponsor Protocol Number: IPH2201-201 Start Date*: 2014-10-20
    Sponsor Name:Innate Pharma
    Full Title: Open label single arm Phase Ib-II study of pre-operative IPH2201 in patients with locally advanced resectable squamous cell carcinoma of the oral cavity
    Medical condition: Locally advanced resectable squamous cell carcinoma of the oral cavity
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071538 Head and neck cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020832-20 Sponsor Protocol Number: P06356 Start Date*: 2010-08-13
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials
    Full Title: An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356)
    Medical condition: This study is going to be conducted in heathy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013766-78 Sponsor Protocol Number: CA191-004 Start Date*: 2010-04-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer Revised Protocol Number 01 (version 2.0, dated 0...
    Medical condition: Advanced or Metastatic Her-2-positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065430 HER-2 positive breast cancer LLT
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001044-38 Sponsor Protocol Number: UMCN-AKF14.01 Start Date*: 2014-07-28
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Influence of an Acidic Beverage (Coca-Cola) on the exposure to Imatinib (GLIvec) after major gastrecTomY in patients with Gastrointestinal Stromal Tumors (ABILITY)
    Medical condition: Patients who are treated or will be treated with imatinib, who previously underwent major gastrectomy.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019214-25 Sponsor Protocol Number: AXP-CT-001 Start Date*: 2010-08-24
    Sponsor Name:Axcentua Pharmaceuticals AB
    Full Title: Safety, pharmacokinetics and efficacy of AXP107-11 in combination with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the ...
    Medical condition: Histologically confirmed, unresectable, locally advanced or metastatic pancreatic cancer stage III-IV
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    16.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004962-18 Sponsor Protocol Number: GT-09 Start Date*: 2006-02-27
    Sponsor Name:ALK-Abelló A/S
    Full Title: A randomised, double-blind, placebo-controlled, multi-centre Phase I Trial investigating the safety of ALK Grass tablet in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (wi...
    Medical condition: IgE mediated allergy (hay fever, rhinoconjunctivitis) to grass pollen (Timothy grass, Phleum pratense) with or without asthma. – Alergia mediada por IgE (Rinoconjuntivitis) a polen de gramíneas (Hi...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004149-16 Sponsor Protocol Number: H3E-ES-S085 Start Date*: 2005-02-16
    Sponsor Name:Lilly S.A.
    Full Title: Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancer
    Medical condition: Locally Advanced, non-Resectable or Metastatic Urothelial Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000402-67 Sponsor Protocol Number: MT-03 Start Date*: 2007-08-01
    Sponsor Name:ALK-Abelló S.A
    Full Title: Estudio multicéntrico, randomizado, doble ciego-placebo en Fase I para evaluar la seguridad en niños del liofilizado oral ALK de ácaros
    Medical condition: Asma alérgica leve a moderada, mediada por IgE, (con o sin rinoconjuntivitis) a los ácaros del polvo doméstico
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000602-44 Sponsor Protocol Number: NVB CA 03 P SP 102 B0 Start Date*: 2004-09-28
    Sponsor Name:Pierre Fabre Ibérica, S.A.
    Full Title: Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado
    Medical condition: Advanced breast cancer (metastatic)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-003829-16 Sponsor Protocol Number: RV-MM-DSMM-0279 Start Date*: 2009-09-15
    Sponsor Name:GMIHO - Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH
    Full Title: An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide...
    Medical condition: relapsed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018392-22 Sponsor Protocol Number: 114182 Start Date*: 2010-03-24
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: Estudio fase I, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna antigripal estacional trivalente (GSK2186877A) adyuvada con varias dosis de AS03, administrada en niñ...
    Medical condition: Vacunación frente a la gripe A y B de niños sanos, de 6 a 35 meses, que no hayan recibido la vacunación antigripal con anterioridad.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059430 Influenza immunization LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004015-35 Sponsor Protocol Number: CMM/EM/2008 Start Date*: 2009-08-25
    Sponsor Name:Fundación Progreso y Salud
    Full Title: ENSAYO CLÍNICO MULTICÉNTRICO FASE I/II ALEATORIZADO Y CONTROLADO CON PLACEBO, PARA EVALUACIÓN DE SEGURIDAD Y FACTIBILIDAD DE LA TERAPIA CON DOS DOSIS DISTINTAS DE CÉLULAS TRONCALES MESENQUIMALES AU...
    Medical condition: Pacientes con esclerosis múltiple secundariamente progresiva, que no responden adecuadamente a los tratamientos registrados.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005074-12 Sponsor Protocol Number: 20070411 Start Date*: 2009-03-04
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Es...
    Medical condition: Part 1: Advanced, treatment-refractory solid tumors Part 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma. --------------------...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer LLT
    9.1 10033604 Pancreatic cancer LLT
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001966-14 Sponsor Protocol Number: AGAL19110 Start Date*: 2012-10-25
    Sponsor Name:Genzyme, a Sanofi Company
    Full Title: A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients with Fabry Disease
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001575-37 Sponsor Protocol Number: AT13387-05 Start Date*: 2014-12-15
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC).
    Medical condition: Non-small cell lung cancer (NSCLC) which represents 85% of all lung cancers.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005718-12 Sponsor Protocol Number: AP26113-11-101 Start Date*: 2012-07-12
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
    Medical condition: Dose Escalation Phase: Histologically confirmed advanced malignancies. All histologies except leukaemia. Dose Expansion Phase: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029105 Neoplasms malignant site unspecified NEC HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001384-68 Sponsor Protocol Number: TMC114FD2HTX1006 Start Date*: 2019-09-19
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Study to Assess the Acceptability of Scored Film-coated darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Tablets in HIV-1 Infected Pediatric Parti...
    Medical condition: Human Immunodeficiency Virus Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Sep 19 00:40:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA